Structures by: Motherwell W. D.
Total: 80
2
C13H18N4O10
Molecular Pharmaceutics (2007) 4, 3 347
a=17.9217(2)Å b=6.17660(10)Å c=15.3751(3)Å
α=90.00° β=105.2120(10)° γ=90.00°
3
(C8H10N4O2),(C6H8O7)
Molecular Pharmaceutics (2007) 4, 3 347
a=7.38740(10)Å b=8.3967(2)Å c=13.5053(3)Å
α=91.3330(10)° β=99.0400(10)° γ=99.5880(10)°
C14H25ClN2
C14H25ClN2
New Journal of Chemistry (2002)
a=7.40022(11)Å b=8.56690(15)Å c=13.69231(32)Å
α=106.2107(14)° β=90.8532(11)° γ=98.7783(12)°
2,3 lutidine pamoate
2(C7H10N),C23H14O6
CrystEngComm (2009) 11, 2 254-260
a=15.197(3)Å b=13.262(3)Å c=15.716(3)Å
α=90.00° β=107.20(3)° γ=90.00°
2,4 lutidine pamoate
C23H14O6,2(C7H10N)
CrystEngComm (2009) 11, 2 254-260
a=8.2989(17)Å b=11.453(2)Å c=16.924(3)Å
α=72.76(3)° β=85.65(3)° γ=77.85(3)°
3,4 lutidine pamoate
C23H14O6,2(C7H10N)
CrystEngComm (2009) 11, 2 254-260
a=11.196(2)Å b=12.653(3)Å c=22.963(5)Å
α=104.32(3)° β=103.24(3)° γ=91.58(3)°
2,6 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=15.733(3)Å b=15.106(3)Å c=7.6047(15)Å
α=90.00° β=98.56(3)° γ=90.00°
2,3 lutidine fumarate
C7H10N,C4H3O4,C4H4O4
CrystEngComm (2006) 8, 11 830
a=9.0541(18)Å b=18.159(4)Å c=9.7343(19)Å
α=90.00° β=91.20(3)° γ=90.00°
2,3 lutidine fumaric acid co-crystal
C14H18N2,C4H4O4
CrystEngComm (2006) 8, 11 830
a=9.8746(4)Å b=7.1925(4)Å c=12.2559(5)Å
α=90.00° β=96.810(3)° γ=90.00°
2,4 lutidine fumarate
C7H10N1,0.5(C4H2O41),0.5(C4H4O4)
CrystEngComm (2006) 8, 11 830
a=3.96530(10)Å b=13.7652(4)Å c=20.0488(6)Å
α=90.00° β=91.6030(10)° γ=90.00°
2,3 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=10.0598(3)Å b=7.3023(3)Å c=12.2512(4)Å
α=90.00° β=97.470(2)° γ=90.00°
2,4 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=4.8672(10)Å b=12.763(3)Å c=14.374(3)Å
α=90.00° β=96.20(3)° γ=90.00°
2,5 lutidine fumarate
C7H10N1,C4H4O4,0.5(C4H2O42)
CrystEngComm (2006) 8, 11 830
a=7.2696(2)Å b=9.1353(3)Å c=11.6311(3)Å
α=84.115(2)° β=72.513(2)° γ=88.763(2)°
2,5 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=4.7197(9)Å b=15.272(3)Å c=12.819(3)Å
α=90.00° β=97.38(3)° γ=90.00°
3,4 lutidine fumarate
C7H10N1,0.5(C4H2O42),C4H4O4
CrystEngComm (2006) 8, 11 830
a=7.0478(2)Å b=10.0870(3)Å c=10.8570(3)Å
α=102.305(2)° β=104.584(2)° γ=107.975(2)°
3,4 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=9.802(2)Å b=6.0385(12)Å c=15.626(3)Å
α=90.00° β=102.49(3)° γ=90.00°
3,5 lutidine fumaric acid co-crystal
2(C7H9N),C4H4O4
CrystEngComm (2006) 8, 11 830
a=8.2345(16)Å b=16.299(3)Å c=6.9681(14)Å
α=90.00° β=108.17(3)° γ=90.00°
3,5 lutidine succinic acid co-crystal
2(C7H9N),C4H6O4
CrystEngComm (2006) 8, 11 830
a=10.464(2)Å b=4.9696(10)Å c=17.113(3)Å
α=90.00° β=95.67(3)° γ=90.00°
C8H7ClNO3
C8H7ClNO3
CrystEngComm (2006) 8, 7 545
a=3.7440(10)Å b=6.0320(10)Å c=18.631(2)Å
α=97.660(10)° β=92.280(10)° γ=90.470(10)°
C24H30Cl2N2O6
C24H30Cl2N2O6
CrystEngComm (2006) 8, 7 545
a=5.0843(3)Å b=8.3131(5)Å c=15.9637(8)Å
α=77.760(3)° β=89.771(3)° γ=74.353(3)°
C18H20N2O6
C18H20N2O6
CrystEngComm (2006) 8, 7 545
a=9.2224(4)Å b=10.0926(5)Å c=10.0772(5)Å
α=90.00° β=113.116(3)° γ=90.00°
C26H36N2O6
C26H36N2O6
CrystEngComm (2006) 8, 7 545
a=36.856(2)Å b=5.1674(2)Å c=29.4327(18)Å
α=90.00° β=112.806(2)° γ=90.00°
C8H10N4O2,C5H8O4
C8H10N4O2,C5H8O4
Chemical communications (Cambridge, England) (2004) 7 890-891
a=13.0129(5)Å b=6.6017(2)Å c=17.1427(8)Å
α=90.00° β=97.8360(10)° γ=90.00°
C8H10N4O2,C5H8O4
C8H10N4O2,C5H8O4
Chemical communications (Cambridge, England) (2004) 7 890-891
a=8.3212(8)Å b=8.6667(8)Å c=11.3636(12)Å
α=68.955(4)° β=78.559(4)° γ=74.236(4)°
2,3 lutidine pamoate
2(C7H10N),C23H14O6
CrystEngComm (2009) 11, 2 254-260
a=15.197(3)Å b=13.262(3)Å c=15.716(3)Å
α=90.00° β=107.20(3)° γ=90.00°
3,4 lutidine pamoate
C23H14O6,2(C7H10N)
CrystEngComm (2009) 11, 2 254-260
a=11.196(2)Å b=12.653(3)Å c=22.963(5)Å
α=104.32(3)° β=103.24(3)° γ=91.58(3)°
2,4 lutidine pamoate
C23H14O6,2(C7H10N)
CrystEngComm (2009) 11, 2 254-260
a=8.2989(17)Å b=11.453(2)Å c=16.924(3)Å
α=72.76(3)° β=85.65(3)° γ=77.85(3)°
Quinol:pyrazine
C6H6O2.C4H4N2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=8.901(3)Å b=7.666(2)Å c=6.984(2)Å
α=90.00° β=90.091(6)° γ=90.00°
Quinol:piperazine
C4H10N2,C6H6O2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=5.7060(15)Å b=6.7599(19)Å c=7.0771(18)Å
α=100.269(4)° β=112.446(3)° γ=90.163(3)°
Quinol:2Morpholine
2(C4H9NO)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.6652(13)Å b=5.5881(11)Å c=20.034(4)Å
α=90.00° β=94.942(4)° γ=90.00°
Hemi-quinol pyridine adduct
C3H3O(C5H5N)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.4990(9)Å b=16.459(2)Å c=7.1794(10)Å
α=90.00° β=112.986(3)° γ=90.00°
Quinol:2Piperidine
2(C5H11N)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=10.4230(15)Å b=5.2619(7)Å c=15.221(2)Å
α=90.00° β=109.920(3)° γ=90.00°
Quinol:2(N-methylmorpholine)
2(C5H11NO)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=6.9612(10)Å b=7.3146(11)Å c=9.659(2)Å
α=106.182(3)° β=104.481(3)° γ=106.201(2)°
Quinol:dimethylpiperazine
C6H14N2.C6H6O2
Acta Crystallographica Section B (2005) 61, 1 46-57
a=8.9620(8)Å b=9.4944(8)Å c=14.7119(13)Å
α=90.501(2)° β=92.919(2)° γ=99.664(2)°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.6510(12)Å b=5.0642(10)Å c=9.3185(19)Å
α=90° β=107.518(4)° γ=90°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.6747(9)Å b=5.0760(4)Å c=9.4753(13)Å
α=90° β=107.832(11)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=3.9846(5)Å b=13.9272(19)Å c=20.699(3)Å
α=90° β=90° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=4.0949(4)Å b=13.875(3)Å c=20.716(3)Å
α=90° β=90° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=8.7086(11)Å b=15.4523(19)Å c=8.7414(11)Å
α=90° β=93.954(2)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=3.9724(5)Å b=12.7328(17)Å c=23.155(3)Å
α=90° β=94.126(2)° γ=90°
C6H5Cl1O1
C6H5Cl1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=4.1096(4)Å b=12.7665(10)Å c=23.181(3)Å
α=90° β=94.201(14)° γ=90°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=5.7168(7)Å b=9.9997(19)Å c=17.868(2)Å
α=90° β=90° γ=90°
C22H8I2O2
C22H8I2O2
Acta Crystallographica Section B (2005) 61, 5 511-527
a=4.2020(10)Å b=20.956(4)Å c=9.276(2)Å
α=90.00° β=100.63(3)° γ=90.00°
C6H5F1O1
C6H5F1O1
Acta Crystallographica Section B (2005) 61, 1 69-79
a=17.1336(10)Å b=8.2766(5)Å c=11.4975(7)Å
α=90° β=100.234(2)° γ=90°
C9H9N3O5
C9H9N3O5
Acta Crystallographica Section B (2005) 61, 5 511-527
a=12.5693(4)Å b=4.85310(10)Å c=17.2663(5)Å
α=90° β=99.1624(15)° γ=90°
Azetidine
C3H7N1
Acta Crystallographica Section B (2005) 61, 5 511-527
a=9.507(3)Å b=9.122(3)Å c=9.790(3)Å
α=90° β=117.469(4)° γ=90°
Paracetamol hemi-dimethylpiperazine
2[C8H9NO2][C6H14N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.6970(9)Å b=11.0240(9)Å c=9.4896(8)Å
α=90.00° β=100.684(2)° γ=90.00°
Paracetamol hemi(N-Methylmorpholine)
2[C8H9NO2][C5H11NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.5749(8)Å b=11.0221(8)Å c=9.3894(7)Å
α=90.00° β=101.145(2)° γ=90.00°
Paracetamol-bipyridine
[C8H9NO2][C10H8N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=11.2906(10)Å b=24.103(2)Å c=11.5526(10)Å
α=90.00° β=96.1484(16)° γ=90.00°
2[C8H9NO2][C4H9NO]
2[C8H9NO2][C4H9NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=7.2791(9)Å b=14.6277(18)Å c=18.303(2)Å
α=90.00° β=90.00° γ=90.00°
Paracetamol hemi-dioxane
2[C8H9O2N],[C4H8O2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=12.421(5)Å b=12.056(4)Å c=13.396(3)Å
α=90.00° β=91.51(3)° γ=90.00°
2-Acetamido-4,5-dinitrotoluene
C9H9N3O5
Acta Crystallographica Section E (2004) 60, 12 o2295-o2297
a=12.5693(4)Å b=4.85310(10)Å c=17.2663(5)Å
α=90° β=99.1624(15)° γ=90°
2-Acetamido-4-nitrotoluene
C9H10N2O3
Acta Crystallographica Section E (2005) 61, 9 o2778-o2780
a=8.2167(2)Å b=13.6406(3)Å c=8.7203(2)Å
α=90° β=107.2307(9)° γ=90°
3-Iodo-2,6-dinitrotoluene
C7H5I1N2O4
Acta Crystallographica Section E (2005) 61, 9 o2836-o2838
a=11.0997(5)Å b=6.9493(3)Å c=12.3296(5)Å
α=90° β=92.084(2)° γ=90°
Paracetamol--morpholine (1/2.5)
C8H9NO2,2.5C4H9NO
Acta Crystallographica Section E (2002) 58, 11 o1290-o1292
a=8.710(4)Å b=9.920(5)Å c=12.385(5)Å
α=102.35(3)° β=108.33(2)° γ=96.68(3)°
2-(p-Nitrophenoxy)terahydropyran
C11H13NO4
Acta Crystallographica Section E (2004) 60, 11 o1923-o1924
a=7.47720(10)Å b=21.9462(4)Å c=6.78280(10)Å
α=90.00° β=102.4910(10)° γ=90.00°
Indomethacin methyl ester
C20H18ClNO4
Acta Crystallographica Section E (2004) 60, 4 o508-o509
a=19.0206(5)Å b=4.83260(10)Å c=19.3092(8)Å
α=90.00° β=97.7390(10)° γ=90.00°
Pamoic Acid
C23H16O6
Acta Crystallographica Section E (2006) 62, 3 o1170-o1172
a=19.7348(7)Å b=4.78768(12)Å c=19.2544(4)Å
α=90° β=108.9622(17)° γ=90°
N-(2-Methyl-3,6-dinitrophenyl)acetamide
C9H9N3O5
Acta Crystallographica Section E (2005) 61, 11 o3888-o3890
a=4.9309(2)Å b=11.7571(4)Å c=8.7944(3)Å
α=90° β=99.8608(14)° γ=90°
Dichloro[(η^5^-cyclopentadienyl)dimethyl(η^5^-3- phenylindenyl)silane]hafnium(IV)
C22H20Cl2Hf1Si1
Acta Crystallographica Section E (2007) 63, 1 m238-m240
a=10.1894(4)Å b=11.0993(4)Å c=9.6940(4)Å
α=91.974(2)° β=108.693(2)° γ=80.501(3)°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=8.564(7)Å b=10.0876(18)Å c=7.6419(12)Å
α=90° β=96.38(3)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=9.3214(11)Å b=10.5932(12)Å c=7.6988(9)Å
α=90° β=95.059(8)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=8.868(9)Å b=10.2833(16)Å c=7.7016(13)Å
α=90° β=95.88(3)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=8.367(8)Å b=9.9317(17)Å c=7.5667(12)Å
α=90° β=96.49(3)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=8.254(4)Å b=9.8542(15)Å c=7.5245(11)Å
α=90° β=96.63(3)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=7.938(7)Å b=9.754(3)Å c=7.481(2)Å
α=90° β=97.03(6)° γ=90°
3-aza-bicyclo(3.3.1)nonane-2,4-dione
C8H11N1O2
Crystal Growth & Design (2008) 8, 2 549
a=8.054(7)Å b=9.782(3)Å c=7.5043(19)Å
α=90° β=96.80(5)° γ=90°
2.(CHBr3)2
4(C8H10N4O2)(C4H6O4)2(C1H1Br3)
Crystal Growth & Design (2008) 8, 5 1605
a=12.0064(4)Å b=33.4489(8)Å c=6.5490(2)Å
α=90.00° β=104.9510(10)° γ=90.00°
2.(CHCl3)2
4(C8H10N4O2),(C4H6O4),2(C1H1Cl3)
Crystal Growth & Design (2008) 8, 5 1605
a=6.64390(10)Å b=23.2514(4)Å c=33.5615(7)Å
α=90.00° β=90.00° γ=90.00°
C8H10N4O2,C4H4O4
C8H10N4O2,C4H4O4
Crystal Growth & Design (2005) 5, 3 1013
a=6.8565(2)Å b=12.5051(4)Å c=15.8362(5)Å
α=90.00° β=93.6100(10)° γ=90.00°
C8H10N4O2,C5H8O4
C8H10N4O2,C5H8O4
Crystal Growth & Design (2005) 5, 3 1013
a=13.0129(5)Å b=6.6017(2)Å c=17.1427(8)Å
α=90.00° β=97.8360(10)° γ=90.00°
C8H10N4O2,C5H8O4
C8H10N4O2,C5H8O4
Crystal Growth & Design (2005) 5, 3 1013
a=8.3212(8)Å b=8.6667(8)Å c=11.3636(12)Å
α=68.955(4)° β=78.559(4)° γ=74.236(4)°
2(C8H10N4O2),C2H2O4
2(C8H10N4O2),C2H2O4
Crystal Growth & Design (2005) 5, 3 1013
a=4.41430(10)Å b=14.7701(5)Å c=15.9119(6)Å
α=90.00° β=96.4850(10)° γ=90.00°
5-fluoro-2-oxindole
C8H6FNO
Crystal Growth & Design (2006) 6, 9 1985
a=4.3901(3)Å b=7.1531(5)Å c=11.0189(8)Å
α=90.00° β=92.880(3)° γ=90.00°
3-quinuclidinol
C7H13N1O1
Crystal Growth & Design (2006) 6, 9 1985
a=6.4549(3)Å b=10.4034(4)Å c=10.1283(5)Å
α=90.00° β=92.9420(10)° γ=90.00°
C6H12O6
C6H12O6
Crystal Growth & Design (2006) 6, 10 2301
a=6.7176(2)Å b=6.7638(2)Å c=8.6217(3)Å
α=95.3550(10)° β=99.6860(10)° γ=98.8790(10)°
Quinol:2(4,4'-bipyridine)
2(C10H8N2)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=7.820(4)Å b=8.619(4)Å c=9.201(4)Å
α=111.897(7)° β=109.851(7)° γ=94.657(8)°
C3H4N2O2
C3H4N2O2
Acta Crystallographica Section B (2005) 61, 5 511-527
a=9.3538(7)Å b=12.1757(11)Å c=7.2286(6)Å
α=90° β=104.593(4)° γ=90°
Paracetamol hemi-piperazine
2[C8H9NO2][C4H10N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=15.893(5)Å b=5.1664(17)Å c=12.993(4)Å
α=90.00° β=113.633(5)° γ=90.00°
2(C8H10N4O2),C3H4O4
2(C8H10N4O2),C3H4O4
Crystal Growth & Design (2005) 5, 3 1013
a=30.3992(12)Å b=31.2845(16)Å c=4.6739(2)Å
α=90.00° β=90.00° γ=90.00°